Travelling towards a bigger, better breast cancer charity

Annual report and accounts 2018–19 (1 April 2018–31 March 2019)
Welcome to Breast Cancer Care’s annual report 2018–19

Travelling towards a bigger, better information, support, campaigning and research charity

It’s been a momentous year for Breast Cancer Care – the end of an era, on which we report in the pages that follow. Also, importantly, it heralded the start of a whole new chapter of charitable activity for everyone affected by breast cancer.

The end of March 2019 saw the last day of Breast Cancer Care as solely an information, support and influencing charity. From 1 April 2019 we merged with research and campaigning charity Breast Cancer Now to become the UK’s first comprehensive breast cancer charity – Breast Cancer Care and Breast Cancer Now.

As 2019 progresses, the new charity is developing quickly, with significant work underway to integrate effectively and let people know about our new charity. We want to ensure that everyone who might need our services, support and information, wants to campaign with us or fundraise for our services, influencing and research, knows who we are now, what we do and where to find us.

Just like the two separate charities, which both had people affected by breast cancer at their hearts, Breast Cancer Care and Breast Cancer Now will be using that ethos to provide support for today and hope for the future. United, we have the ability to enable even more world-class research, provide even more life-changing support and campaign even more effectively for better services and care.

So – despite some inevitable nostalgia for Breast Cancer Care, which sprang from the visionary work of one woman, Betty Westgate, more than 40 years ago – we believed it was in the best interests of everyone affected by breast cancer to pool our resources.
More than £1 million going towards established Investment in digital fundraising so that people can donate to us more easily, and in making breast cancer and breast awareness information much more accessible so that we can reach even more people.

This overwhelmingly generous contribution is enabling us to do more for people affected by breast cancer, and faster than we previously thought possible. We are immensely grateful for it, and the work is continuing into 2019–20 and beyond.

Asda is another huge and long-term contributor to supporting people affected by breast cancer. This is mostly through the Tickled Pink campaign, under which Breast Cancer Care and Breast Cancer Now have collaborated for many years. We are delighted that we are set to continue our partnership post-merger, raising even more money for breast cancer services, to disseminate the vital breast awareness messages and to fund research.

On the digital front, the National Lottery Community Fund grant of £655,000 has enabled great progress on our breast cancer support BECCA app personalisation project. The app supports people during the often very difficult period when treatment has ended and the impact of what you have just been through starts to sink in. At this time, people can feel vulnerable, anxious, isolated and low.

The work enabled by the grant this financial year has led to the launch in May 2019 of a new BECCA feature that personalises the information ‘cards’ that users of the app see each day. In-year, we have been able to increase the number and range of support cards served by the app using innovative technology.

But it isn’t only large donations for which we are grateful. It makes our work seem even more worthwhile when someone tells us, for example, how invaluable they’ve found our publications or website information, and they add a much-needed donation. Or when the many companies we work with help to inspire and enable staff and customers to raise funds for us. And we couldn’t keep going without the thousands of marathon runners, cyclists, swimmers, walkers, bakers, fashion friends and party people who bring in even more money to support more people affected by breast cancer – so very often, we know, because they, their family or friends have a had breast cancer diagnosis.

We are only too aware that right now, well over half a million people are living with the impact of a breast cancer diagnosis, and that thousands of people are still dying from this disease every year – most of them women but men among them too. And for each diagnosis, many more people are affected: family, friends, colleagues and the amazing healthcare professionals who work so hard to deliver the best possible treatment and care.

Many of the people affected join forces with us in other ways too. For example, campaigning for better breast cancer care, volunteering for vital roles in our support services and joining mutual support groups, such as our web-based Forum. Our gratitude and thanks also go out to these people.

We hope every one of you will continue to travel with us as we bring together our combined heritage, passion, energy, expertise, funds and networks to drive greater progress through research, campaigning, information and support in the prevention, detection, treatment and care – both physical and emotional – of every breast cancer patient, now and in the future.

Thanks to everyone for all that you do – we couldn’t do our work without you.

Delyth Morgan,
Chief Executive, Breast Cancer Care and Breast Cancer Now

Jill Thompson,
Chair of the Breast Cancer Care and Breast Cancer Now Board of Trustees
Who we are and what we do: a summary of our activities for 2018–19

A breast cancer diagnosis changes everything. At Breast Cancer Care we understand the emotions, challenges and decisions people face when they – or a family member or friend – hear the words, ‘It’s breast cancer’.

We know that everyone’s experience is unique. That’s why we offer reliable, practical support and trustworthy information, bringing together people affected by breast cancer to help each other and campaign for better care.

We are the only specialist UK-wide charity supporting people with breast cancer. We combine the personal experience of people affected by the disease with clinical expertise, delivering free services that make life better for people facing the trauma of breast cancer. These include:

- Support over the phone or by email with a breast care nurse or someone who’s been there
- Welcoming online forums
- High-quality information in traditional and digital formats
- Group support
- Real-time digital support sessions

We help people to live with breast cancer and beyond, involving people affected by breast cancer in everything we do. From the moment someone notices something isn’t right, through their treatment and into the future, Breast Cancer Care is here.

And we’re here for people concerned about breast cancer. We help them to be breast aware so that they can notice any unusual changes in their breasts and be confident to report them to their GP. Most breast symptoms aren’t caused by breast cancer. This will ensure that we are providing the high-quality information and support that people want, and which will make a vital difference to how they cope with a life-changing diagnosis of breast cancer.

We know we are succeeding substantially in this aim because, even as we began merger work, we continued to deliver more hours of support and respond to more requests for breast health and breast cancer information in a wide variety of accessible formats.

Hundreds of campaigning volunteers worked with us to try to improve standards of care for everyone affected by breast cancer. And nurses throughout the UK gave out or signposted people to our patient information, both as booklets and on our website. These resources are written by our nursing team and peer reviewed by independent healthcare professionals and people with breast cancer. New editions are created every two to three years to help ensure they are always up to date. Breast Cancer Care patient information is now freely available on 166 volunteer-run Information Points in breast care units, hospitals and other locations across the UK.

Members of our Nursing Network, of which there are now 1,241, are prominent among healthcare professionals volunteering to help us ensure the quality of our patient information and our support services. Using the Network – run by our Clinical team – they share best practice, discuss ways of bringing about local service improvements and take part in training opportunities, both as participants and trainers.

We particularly rely on the expertise of nurses from the secondary breast cancer and younger women with breast cancer Network groups.

As our new Chief Executive Delyth Morgan and Chair of Trustees Jill Thompson spell out on page 3, all this work and more is going to continue as we join together to create a stronger and more passionate workforce delivering support, care, information and hope to people whose world has been turned upside down by a breast cancer diagnosis.
Strategic report: aims and objectives

Our overarching aims and objectives for 2018–19 were:

- Reach more people with support services, care and information
- Raise our profile to help improve standards of care and treatment
- Raise more money to help people affected by breast cancer

The figures that follow demonstrate how we have performed in meeting those objectives.

Reaching more people

We set targets for increasing our reach guided by our Services and influencing strategy 2016–20. Most 2018–19 targets for services were achieved or exceeded, meaning we supported 1,190 more people affected by breast cancer through our face-to-face and Someone Like Me services than we did during 2017–18.

The Someone Like Me service, which matches people by phone or email with a trained volunteer who has been through a similar experience, found that they may have missed a screening invitation because of a technical error in PHE’s systems.

To help ensure healthcare professionals all over the UK know about and understand the free services to which they can refer people affected by breast cancer, we produced a new brochure Stronger Together. This important marketing, to ensure we reach more people who need our services, was funded by a £1 million Tampon Tax Grant we received from government in 2016–17.

Altogether between April 2018 to March 2019, we provided well over 55,000 hours of support through our services, an increase of 20.8% on 2017–18.

The excellence of our breast cancer support app BECCA was recognised when we won Best Health Project at the 2018 National Lottery Awards. Chosen from over 700 National Lottery-funded UK projects as a finalist, BECCA beat six other category nominations and has been awarded £5,000 to go towards the project. This amazing award means we can empower even more people to live life with confidence after breast cancer.

We had 4,107,264 unique visitors to our website during 2018–19, with reach increased by 48% as 1,335,506 more unique visitors came to the site during 2018–19.

In addition to patient information delivered through our website pages, 1,231,140 patient information publications were distributed or downloaded as e-books or in PDF format during 2018–19, an increase of more than 8% on distribution in the previous year.

From our 2,504 Breast Cancer Voices we recruited many lay reviewers of our patient information. They check it to ensure it reads well and makes sense to patients. The Voices are volunteers with direct experience of breast cancer, who contribute to our work in a variety of ways, helping us to ensure we always keep people affected by breast cancer at the heart of our work.

Our patient information booklet Breast cancer in younger women took one of the top prizes at the 2018 BMA Patient Information Awards, in the Diversity, Equality and Inclusion category. We were also highly commended in two other categories with our booklets about coping with hair loss and understanding your pathology report.

This is a great reflection of the quality of our patient information. There are hundreds of entries to these awards, which are judged by leading clinicians and patient information experts.

During 2018–19 we responded to nearly 7 million breast cancer support requests. That’s 1.1 million more than during 2017–18.*

<table>
<thead>
<tr>
<th>Website section</th>
<th>Number of unique visitors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Breast awareness</td>
<td>1,866,509</td>
</tr>
<tr>
<td>Diagnosis and treatment</td>
<td>787,682</td>
</tr>
<tr>
<td>Moving Forward</td>
<td>201,297</td>
</tr>
<tr>
<td>Secondary breast cancer</td>
<td>312,281</td>
</tr>
<tr>
<td>Younger women</td>
<td>23,665</td>
</tr>
<tr>
<td>Breast cancer in families</td>
<td>15,777</td>
</tr>
<tr>
<td>Someone I know has breast cancer</td>
<td>10,219</td>
</tr>
</tbody>
</table>

$^*$ Figures aggregated from: online Forum and unique website visitors; social media followers; BECCA app downloads; Helpline calls and Ask Our Nurses queries; patient information distributed and downloaded; people supported by face-to-face and Someone Like Me services; Nursing Network members. Total 6,966,642.
Raising our profile: influencing and campaigning

Care After Breast Cancer: it shouldn’t end at treatment

In July 2018, we launched our campaign Care After Breast Cancer to press for improvements in support after hospital-based treatment for people with a diagnosis of primary breast cancer. The campaign used results from a Freedom of Information (FoI) request and a survey of nearly 3,000 women in England to highlight the need for specialised, ongoing support after hospital treatment for primary breast cancer.

This research revealed significant gaps in breast cancer-specific support after hospital-based treatment. To tackle these gaps, we asked campaigners and supporters in England to contact their MPs and to write to Cancer Alliances highlighting these findings and urging them to ensure everyone has access to such support. In Scotland and Wales we asked campaigners to write to their MSP (member of the Scottish Parliament) or AM (Welsh Assembly Member) asking them to contact their Cancer Network or Health Board to ensure a breast cancer-specific support event is a formal part of the breast cancer pathway.

1,390 people wrote to their MP, MSP or AM, leading to 34 of them writing to their Cancer Alliance, Cancer Network, Health Board or health minister.

During a campaign launch at the Westminster Parliament in July 2018, Stelios, the face of the campaign (pictured on page 13), spoke with MPs about the need for breast cancer-specific support. The 32 MPs who attended were also offered a personalised briefing showing the support available in their local area.

As a result of the campaign, we met with Cancer Alliances and the Department of Health and Social Care to discuss the findings and our recommendations. The campaign also led to an increase of around 1,000 supporters signing up to work with us through our Campaigns Network.

Secondary. Not Second Rate: incurable shouldn’t mean unsupported

We have been campaigning to improve care and support for people with secondary breast cancer since 2006, most recently through our Secondary. Not Second Rate campaign, which highlighted issues in diagnosis, data collection, support services and nursing care.

In August 2018, we updated the findings from this campaign through an FoI request to all hospital trusts and health boards. The findings showed that:

- 72% of hospital organisations in England, Scotland and Wales did not provide people with secondary breast cancer access to a dedicated specialist nurse
- Two-fifths could not let us know how many secondary breast cancer patients were currently under their care
- 70% did not assess people’s emotional and physical needs when diagnosed and as their treatment changed

In light of these findings, we used Secondary Breast Cancer Awareness Day (13 October 2018) to campaign for the introduction of a Secondary Support Package. We published our Secondary. Not Second Rate: incurable shouldn’t mean unsupported briefing, setting out the support the package would include as follows:

- Access to a designated clinical nurse specialist (CNS) with relevant skills, knowledge and experience of secondary breast cancer
- A discussion of emotional, physical and information needs with a healthcare professional through a holistic needs assessment at key points throughout treatment
- A treatment summary at the end of each significant phase of treatment
- A referral to a tailored health and wellbeing service that includes psychological support and opportunities to meet others with secondary breast cancer

We asked campaigners to contact their MPs, MSPs, AMs and MLAs (member of the Legislative Assembly, Northern Ireland) pressing them to show their support for the campaign by signing up to a letter to the relevant health ministers asking them to introduce a Secondary Support Package.

Over 2,000 campaigners (nearly half of our Campaigns Network) took the action, resulting in 66 politicians endorsing the package of support measures.

There was significant national and local media coverage, including on BBC Radio 4’s Today Programme and Channel 4 News.

It has resulted in progress across the UK:

- The NHS England Long Term Plan included a commitment to providing nursing support for people with secondary cancers, such as secondary breast cancer
- The Welsh Government has now established a Task and Finish group to assess the need for secondary breast cancer nurses
- The Scottish Government is producing recommendations to improve secondary breast cancer services

There were 4,354 registered Campaign Network members at the end of 2018–19, an increase of more than 1,000 members over 2017–18.

Breast cancer guidance and access to new treatments

Our nurses and policy leads are involved in breast cancer drug appraisals for the National Institute for Health and Care Excellence (NICE) in England and Wales, and the Scottish Medicines Consortium (SMC) in Scotland. We work to ensure that the voices of people affected by breast cancer are heard in these appraisals.

During 2018–19, we provided submissions to the following appraisals:

- Palbociclib for treatment of hormone receptor positive, HER2 negative, locally advanced or metastatic breast cancer in combination with fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy (these were two separate submissions – one for AI and another for fulvestrant)
- Pertuzumab in combination with trastuzumab and docetaxel in patients with HER2 positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease

Pertuzumab in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of patients with HER2 positive, locally advanced, inflammatory or early stage breast cancer at high risk of recurrence

We also provided commentary for the development of NICE’s Early and locally advanced breast cancer: diagnosis and treatment guidance. NICE incorporated our call for the guidance to include reference to fertility issues, including a cross-reference to the NICE guideline on the assessment and management of fertility problems. This fertility guideline includes a section on people with cancer who wish to preserve their fertility. Inclusion of this link will increase awareness for people affected by breast cancer and healthcare professionals about the need to consider the potential impact of cancer treatment on fertility when providing information and support to people with breast cancer.

Our Clinical Director represented Breast Cancer Care on the following advisory bodies and steering committees:

- NHS England Breast Cancer Clinical Expert Group
- National Audit of Breast Cancer in Older Patients in England and Wales
Policy networks in England, Scotland and Wales

We routinely play a part in healthcare policy and decision-making, and consult with cancer patients, organisations and government on cancer services and NHS care pathways for people with cancer. We are committed to ensuring the needs and voices of people with cancer are heard at the highest level.

We have been advising NHS England on best practice for breast cancer diagnosis, treatment and care through the Breast Cancer Clinical Expert Group as well as the Cancer Patient Experience Advisory Group. We are also represented on the Cancer Campaigning Group, which brings together more than 60 cancer charities and organisations.

As part of our representation on these groups, we played a key role in the Cancer Patient Experience Survey in England following implementation of the National Data Guardian for Health and Social Care’s recommendations.

In Wales we have representation on the Cancer Implementation Group and Cross-Party Group on Cancer. We also co-chair a newly formed Task and Finish Group to assess secondary breast cancer specialist nursing provision.

In Scotland we sit on the Cancer Coalition Group and the Cross-Party Group on Cancer. We also co-chair a newly formed Task and Finish Group to assess secondary breast cancer specialist nursing provision.

Breast Cancer Care volunteers contributed 5,047 hours to deliver our services and campaigning activity during 2018–19 and 2,359 hours to deliver organisational support, and fundraising and marketing activity.

We have been offered some wonderful awareness-raising opportunities by our corporate and other supporters. For example, we worked with the Evening Standard as their named charity sponsor for their health and wellbeing event series (The ReSet). This gave us access to significant advertising space with the newspaper, including two cover wraps – produced by our in-house designer and photographer – of the London Evening Standard, allowing us to reach an audience of over 7 million people.

We were also approached by the Leo Burnett advertising company to collaborate on a breast awareness campaign: Booberang. This work included a short film that received tens of thousands of organic views and helped drive traffic to our campaign landing page. New audiences made up 80% of the traffic. This year’s activity has contributed to a rise in our brand awareness. Our Booberang campaign video received positive recognition at the 2019 Charity Film Awards, winning the Film of the Year Award in our category.

In addition, our Press and Public Relations team works across a range of activity, for example coordinating charity spokespeople’s comments on issues of public interest such as government policy and the NHS. The team also focuses on raising awareness about breast cancer and the impact it has on people’s lives – giving people affected a platform to share their experiences and promoting our free information and support services as well as the events that bring in funds to help run these services.

Over the year the team issued six proactive news stories, including in support of our Care After Breast Cancer and Secondary Breast Cancer campaigning work (see page 10). They also placed strong case study stories and clinical features, issued comments and letters to editors, overall securing 3,493 pieces of coverage during 2018–19. As a result, for six months of the year Breast Cancer Care was in the top 50 in the league table for charities appearing in mainstream media.

Media coverage in the lead-up to and during Breast Cancer Awareness Month (September and October 2018) increased dramatically over the previous year to more than 402 million circulation (compared to 194 million total circulation in 2017). This was a record-breaking amount of coverage for Breast Cancer Care. Coverage included a Secondary Breast Cancer Awareness Day news story that secured the charity’s first live studio interviews on Radio 4’s Today programme and Channel 4 News.

Breast Cancer Awareness Month media coverage, Sept–Oct 2018

<table>
<thead>
<tr>
<th>Outlet</th>
<th>Articles, quotes and interviews</th>
</tr>
</thead>
<tbody>
<tr>
<td>National newspapers</td>
<td>56</td>
</tr>
<tr>
<td>Consumer magazines</td>
<td>37</td>
</tr>
<tr>
<td>Regional press</td>
<td>342</td>
</tr>
<tr>
<td>Online</td>
<td>100</td>
</tr>
<tr>
<td>Trade press</td>
<td>3</td>
</tr>
<tr>
<td>Broadcast</td>
<td>40</td>
</tr>
<tr>
<td>Total number of cuttings</td>
<td>1,368</td>
</tr>
<tr>
<td>Total circulation</td>
<td>40,251,528</td>
</tr>
</tbody>
</table>

Here are some of the other highlights of our press and public relations activity:

- Over 250 pieces of coverage in May 2018 following Public Health England’s breast screening programme errors, reaching a circulation of over 5.4 million and raising the profile of our Helpline.
- A feature in the Daily Express and Daily Mirror tied to our news story at the start of 2019 about diet and exercise to help promote our support services, with a circulation of 1.4 million. The story was also featured in Take a Break magazine with a circulation of over 460,000.
- Breast Cancer Care was aligned with ITV drama series Cold Feet’s breast cancer storyline. Our nurses advised on the script, and our support and contact details were on the ITV website and given at the end of episodes. Our supporter Fay Ripley, who stars in the show, talked about our support and information services when interviewed on ITV’s This Morning. Woman and Home magazine’s website included the charity’s signs and symptoms infographic, a link to our website and mention of our Helpline and Forum.
Raising more money: a record year for fundraising

Despite another year of uncertainty and a variety of challenges for charities, supporters and donors alike, we achieved record levels of fundraising and income generation during 2018–19.

We are funded by voluntary donations, trusts and corporate support, to all of whom we are extremely grateful for helping us to achieve this outstanding outcome in difficult circumstances (see Our finances page 20 and Financial statements and notes pages 20–38). We rarely receive any government funding.

A change in our Director of Fundraising and Marketing in 2017 combined with a new perspective on our approach to fundraising and marketing throughout 2018 and into 2019 delivered benefits in our planning, results, awareness and overall income performance. This has helped us to be even more confident of the care we take with our fundraising, especially when individuals are trusting us with their personal details and money.

We want people to feel certain that, when they give to Breast Cancer Care, we put their money immediately to good use, helping people affected by breast cancer to make the right choices for them and to cope better with this life-threatening diagnosis.

We are incredibly grateful to all our corporate partners who continue to provide such invaluable support. Special and huge thanks as ever go to Adda, which has now raised more than £64 million through the Tickled Pink campaign over the past 22 years. Tickled Pink supports both Breast Cancer Care and Breast Cancer Now, through colleague and customer fundraising, supplier-supported products and communication campaigns. The partnership continues to raise crucial awareness of the importance of early breast cancer detection and funds for our support and information services.

With the ongoing support of all our corporate partners, we have been able to help thousands of people affected by breast cancer with our support services, while reaching a record number of people through their businesses.

A special mention also to the players of the People’s Postcode Lottery who, for the first time in partnership with Breast Cancer Care, raised an incredible £3 million to support people affected by breast cancer.

Our thanks as well to SportsPesa Racing Point F1 Team, BWT, Skechers, Dorothy Perkins, Palmers and ELEMIS, whose continued support and significant contributions have enabled us to offer care and information to thousands of women and men affected by breast cancer, reaching even more people with our support services.

Another incredible source of support is from the 23 dedicated members of our giving club, the Care Collective. They have been working steadily towards a £1.5 million target to help us double the reach of our face-to-face services. Over three years they have now contributed more than £500,000 towards this target. We can’t thank them enough for their time, energy and donations delivering this vital initiative.

We have also been building on long-term, strategic partnerships with trusts, foundations and individuals, receiving gifts from 24 trusts new to the charity in 2018–19.

You can see more of our wonderful partners and other supporters on page 40.

In 2018–19, over 70,000 individuals have helped us plan for the future with confidence by supporting our raffles and lottery, by setting up regular payments by direct debit and continuing to remain an important part of our fundraising efforts. The reliable income we receive in this way is crucial in enabling us to deliver sustainable services to people affected by breast cancer.

Last year we were very grateful that 49 people remembered Breast Cancer Care’s work in their wills, the highest number of legacies we’ve received in the charity’s 46-year history.

People support us all year round in a variety of different ways, from buying goods at our three charity shops in Leighton Buzzard, Hemel Hempstead and Peterborough to ordering gifts or donating via our website.

To help support people affected by breast cancer visit breastcancercare.org.uk/donate

Through our mass participation community and events programme, thousands more people have raised funds to help people affected by breast cancer. These activities include our Pink Ribbon Walks, Afternoon Teas and Big Pink events, running, cycling, modelling and so much more.

We held two Pink Ribbon Walk events in 2018–19, returning to Blenheim Palace in Oxfordshire for the 14th time and at Audley End in Essex for the first time, raising in excess of £300,000.

Since their launch 14 years ago, there have been more than 40,000 participants in our flagship Pink Ribbon Walks, raising a total of £12.4 million.

We achieved a record for our Afternoon Tea fundraising campaign in 2018–19 with supporters holding more than 2,000 Afternoon Teas. The funds they raise at these events have contributed to more than £7 million raised by people holding Strawberry and Afternoon Teas since the event launched in 1998.

We also had our best ever fundraising performances from our runners taking part in the Virgin Money London Marathon, up 8% against 2017–18, and the Royal Parks Half Marathon, up by 18% against 2017–18.

During 2018–19 there were:

- 1,200 Pink Ribbon Walkers
- More than 2,000 Afternoon Teas
- 2,225 people taking part in a variety of sporting and challenge events

Our fashion shows are among the highlights every year and have been since their launch in 1992. They are a unique and special opportunity to engage a wide range of audiences through a gala event format with models who have all had a diagnosis of breast cancer. The Show London and Show Scotland were attended by 1,948 guests and raised over £440,000 in 2018–19. Overall, The Shows have raised an incredible £10.3 million since inception.

Not only do these events raise money for us but they also help people who have been through breast cancer to get together and demonstrate that it’s possible to regain your confidence and much more after such a traumatic diagnosis.

Most of our fundraising events are supported by staff volunteering their time outside their normal working hours.

Travelling forward together

Since Betty Westgate founded Breast Cancer Care in 1973, or the Mastectomy Society as it was then called, we have been through several transformations. We’ve grown from a one-woman band based in Croydon, South London, to a nationwide organisation of more than 200 people working to support, care for and inform people affected by breast cancer.

On 1 April 2019, we expanded yet again to become Breast Cancer Care and Breast Cancer Now, encompassing a dynamic portfolio of life-enhancing research into the causes, treatment and – we fervently hope – eventual cure of breast cancer. But until that day comes, we will also still be here working to make sure that everyone affected by breast cancer gets the best treatment, information, support and care available.

We are united in the aim that, by 2050, everyone who develops breast cancer will live, and everyone will receive the support they need to live well now.

Thanks to you all for travelling with us, now and in the future.
Our structure, governance and management

Please note: The following details applied to Breast Cancer Care up to 31 March 2019, the time period covered by this report. Thereafter Breast Cancer Care became part of a new united charity under the name Breast Cancer Care and Breast Cancer Now, with different charity details, structure, governance and management. Due diligence was applied in making these changes, taking into consideration the arrangements of both the uniting charities. For more details visit breastcancercare.org.uk/united

Up until 31 March 2019
Breast Cancer Care is a company limited by guarantee and registered in England, no 2447182. It is a charity, registered in England and Wales in 1993, no 1017658, and in Scotland in 2007, no SC038104, and it was incorporated in 1989. The charity was governed by the company’s Memorandum and Articles of Association.

The Board
Members of the Board have two roles: first, as directors of the company in company law and, second, as trustees of the charity.

Recruiting and training trustees
Applications for Board membership are sought openly through external advertisement. The Governance and Nominations Committee, with the involvement of the Chief Executive, selects, interviews and proposes suitable candidates for the role of trustee to the whole Board for approval. Appointments are made according to relevant skills, competencies and experience. Breast Cancer Care endeavours to ensure that at least one-third of its trustees have been personally affected by breast cancer. At 31 March 2019, six of ten trustees had had breast cancer, and all of them had been personally affected by breast cancer in some way. In accordance with best practice, term limits are in place for all trustees. We recognise the responsibilities placed by law on a charity trustee and therefore offer a programme of training for all trustees including a full and formal induction programme for new trustees. All trustees have a review meeting about once every 18 months with either the Chair or Vice-Chair. The Chair carries out a review with the Vice-Chair and vice versa.

Statement of trustees’ responsibilities
The trustees are responsible for preparing this report and the financial statements in accordance with applicable law and United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards). Company law requires the trustees to prepare financial statements for each financial year. Under company law the trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the charitable company and the group; and of the incoming resources and application of resources, including the income and expenditure, of the charitable group for that period. In preparing these financial statements, the trustees are required to:

• Select suitable accounting policies and then apply them consistently
• Observe the methods and principles in the Charities Statement of Recommended Practice (SORP)
• Make judgements and estimates that are reasonable and prudent
• State whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements

The trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the charitable company’s transactions, and also to disclose (with reasonable accuracy and at any time) the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005, the Charities Accounts (Scotland) Regulations 2008 (as amended) and the provisions of the charity’s constitution. They are also responsible for safeguarding the assets of the charity and the group and hence for taking reasonable steps for the prevention and detection
of fraud and other irregularities. Each trustee confirms the following to our independent auditors.

1. So far as the trustee is aware, there is no relevant audit information of which Breast Cancer Care’s auditors are unaware.

2. The trustee has taken all the steps that she or he ought to have taken as a trustee in order to make herself/himself aware of any relevant audit information and to establish that Breast Cancer Care’s auditors are aware of that information.

This confirmation is given and should be interpreted in accordance with the provisions of section 234ZA of the Companies Act 2006.

Public benefit
The trustees confirm that they have complied with their duty under the Charities Act 2011 to have due regard to the public benefit guidance published by the Charity Commission in determining the activities undertaken by the charity. We are confident that our whole approach to equality of access (as detailed in our vision statement) meets the highest aspirations of the public benefit policy and that our reported achievements will ensure we maintain that vision.

Organisational structure and decision-making
The Board of Trustees has legal responsibility for the effective use of resources in meeting the charity’s objects and for providing effective leadership and direction. They meet quarterly and, at least once a year, they have a half day of team-building, in-depth discussion and debate. They also have access to a range of training opportunities.

Sub-committees
The Board of Trustees delegates some of its authority to the following sub-committees: Finance and General Purposes, Audit and Assurance, Investment, Human Resources and Remuneration, and Governance and Nominations. Each sub-committee has specific terms of reference and functions delegated by the Board, and a Chair and members, including co-optees who are not trustees, appointed by the Board. In the case of the Audit and Assurance Committee, the Chair is appointed after an open recruitment and interview process and may either be a trustee or from outside the Board but with specialist skills suited to the role. The current Chair is a member of the Board of Trustees. A complete list of the sub-committees of the Board and their members plus Breast Cancer Care’s advisory committees is available at the end of this document. Management responsibility for day-to-day management matters and the implementation of policy is delegated to the Chief Executive, supported by the Senior Management team.

Employees
Breast Cancer Care’s staff play a key role in the success of the organisation. Their commitment and specialist skills are central to the delivery of our high-quality, wide-ranging services for people affected by breast cancer. We are committed to supporting, developing and effectively managing our staff. Our Human Resources team provides a wide range of support, guidance and development opportunities for staff so that we continue our culture of learning and retain talent.

Staff remuneration
The majority of employees are paid in line with existing public sector pay scales, including any annual award for cost of living increases. Staff salaries are either pegged to the National Joint Council (NJC) pay scale, typically used within local authorities, or the Agenda for Change (AfC) scale, which is used within the NHS. The Chief Executive and Senior Management team’s pay is set and reviewed annually by the Human Resources and Remuneration Committee, a sub-committee of the Board of Trustees with delegated powers, in accordance with an established procedure that aims to be transparent, sustainable, proportionate and performance-based. Like other employees, Senior Management team members are entitled to a cost of living increase (the NJC award) though they are not eligible for incremental pay rises. However, should specific criteria be met, they may receive a non-consolidated payment, capped at 5% of gross pay. This depends both on them individually achieving a range of objectives and the overall financial strength of the charity.

Further details can be found in Note 10 to the financial statements.
Our finances

On 31 March 2019 the activities, assets and liabilities of Breast Cancer Care were transferred to Breast Cancer Now (subsequently renamed Breast Cancer Care and Breast Cancer Now). As a result, these accounts reflect 12 months of activities with a transfer of the assets and liabilities on the last day of the financial year.

Breast Cancer Care had a highly successful year with income significantly higher than in the previous two years at £19.5m (2017–18 £16.9m, 2016–17 £16.2m) despite a difficult economic backdrop and the uncertainty generated by Brexit.

In addition to the growth of income, we have also carefully controlled costs to enable more funds to be invested in the delivery of our charitable activities (2018–19 £3.4m, 2017–18 £3.9m).

This in-year performance would have resulted in a surplus for 2018–19 of £4m (2017–18 deficit of £174k) before the transfer of funds to Breast Cancer Now.

Our fundraising approach

Scrutiny over fundraising activities and new regulations ensuring that the use of personal data is taken very seriously has meant that we have continued to make these areas a priority.

Breast Cancer Care is proud to say that we put our supporters at the heart of everything that we do especially as they are often people affected by breast cancer and therefore also beneficiaries. We are registered with the Fundraising Regulator and adhere to their code of fundraising when carrying out our activities.

For some activities it is more cost effective for us to work with third party fundraisers. When we do, we ensure that they are thoroughly trained on the charity’s objectives and carry out their activities with the same care that we would ourselves. We do this by regular monitoring of their activities, including shadowing of fundraisers, review of phone calls made and ‘mystery shopping’ activities. We also mystery shop our own Supporter Care team to ensure our high standards are maintained in this important public-facing function.

We operate a clear and stringent complaints and compliments handling procedure that is reported regularly to the Senior Management team and the Board of Trustees. This year we received a total of 77 fundraising complaints. We are mindful of protecting the public, including vulnerable people, from unreasonably intrusive or persistent fundraising approaches, and make use of agreed policies with the external fundraisers that we employ to help us with this.

Risk management

Risk is inherent within all of our activities and therefore must be understood and managed. Accepting a certain level of risk allows us to innovate and strive to achieve more for people affected by breast cancer. It is important, however, to balance risk across the organisation to ensure that it remains within our current level of appetite and tolerance.

We operate a process of risk identification and management that is embedded into the governance of the organisation. Central to this is our risk register, which is regularly reviewed and updated by the Senior Management team and the trustees, and considered by the Finance and General Purposes Committee four times a year.

We also regularly adapt the format and content to ensure we capture our understanding of our biggest risks and what we need to do to manage them. It is a living document that continues to change over time in response to internal and external stimuli.

Major risks are grouped under five categories and scored in terms of likelihood and impact. This allows us to quickly identify the most pressing risks and any changes in their profile. For each risk the register sets out the possible causes, current controls in place to manage it and any actions ongoing to provide further mitigation. These actions are assigned an owner, and progress is tracked by the Senior Management team and the trustees.

Our principal risks remain largely unchanged from the previous year, and revolve around our ability to raise income to fund our services and our ability to increase the number and diversity of people who can access our services.

Almost all the money we spend on our services is raised in the same year, meaning that our planned activities are at risk from volatility within our income streams. Part of our fundraising strategy is to diversify our income to help mitigate against this. Our income is also at risk from changes in the economic environment, public trust in charities and changing fundraising regulation, all of which we monitor closely and respond to through our in-year plans.

As the number of people affected by breast cancer in the UK continues to rise, there is a risk that the reach of our services cannot keep pace. To meet this challenge, post-merger with Breast Cancer Now in 2019, our Services and Influencing strategy (last updated in 2016) will continue to evolve at pace as we develop and refine a more scalable model of service delivery, making it easier to scale up our activities when funds allow.

Investment policy

We held a portion of our reserves as investments in order to protect against their erosion through inflation in the medium to long term. Our objective is to balance income and capital return to enable us to provide services for our beneficiaries in the present and in the future, against an acceptable level of risk. We are currently holding a low-risk-tolerance position, reflecting the ongoing economic uncertainty. Investments are sufficiently liquid that they can be redeemed in a short period of time if required.

We have an ethical policy that means we will not invest directly in tobacco-related companies or companies that derive significant revenue from tobacco-related products. We require that our investment managers exercise care to ensure that tobacco-related companies do not form a material component of any investments made ‘indirectly’ through collective funds.

At the year end, the value of investments was nil due to the transfer of the assets of the charity to Breast Cancer Now.

Reserves Policy

It had been our practice to retain a level of reserves in line with good financial practice to enable the effective running of the organisation. With the merger with Breast Cancer Now, the activities, assets and liabilities of the charity have been transferred to Breast Cancer Now and therefore the charity no longer has a need to retain reserves for future operations. As a result reserves at the year end are nil.

In previous years, the financial statements have been produced on a going concern basis. However, during 2018–19 the trustees took the decision to cease operations following the transfer of the charity’s assets, liabilities and activities to Breast Cancer Now, subsequently renamed as Breast Cancer Care and Breast Cancer Now. As a result the accounts have not been prepared on a going concern basis. Breast Cancer Care is now a wholly owned subsidiary of Breast Cancer Care and Breast Cancer Now.

Jill Thompson,
Chair of the Breast Cancer Care and Breast Cancer Now Board of Trustees
Independent auditor’s report to the members and trustees of Breast Cancer Care

Opinion
We have audited the financial statements of Breast Cancer Care for the year ended 31 March 2019 which comprise the Consolidated Statement of Financial Activities, the Consolidated and Charity Balance Sheets, the Consolidated Cashflow Statement and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102, The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:
• Give a true and fair view of the state of the group’s and the charitable company’s affairs as at 31 March 2019 and of the group’s incoming resources and application of resources, including its income and expenditure for the year then ended;
• Have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
• Have been prepared in accordance with the requirements of the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and Regulations 6 and 8 of the Charities Accounts (Scotland) Regulations 2006 (amended).

Basis for opinion
We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor’s responsibilities for the audit of the financial statements section of our report. We are independent of the group in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern
We draw attention to the disclosure made in Note 1 to the financial statements. The trustees have transferred all the assets and liabilities of the charitable company to Breast Cancer Now and cease activities at 31 March 2019. As required by UK accounting standards, the trustees have prepared the financial statements on the basis that the company is no longer a going concern. Our opinion is not modified in respect of this matter.

Other information
The trustees are responsible for the other information. The other information comprises the information included in the annual report, other than the financial statements and our auditor’s report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006
In our opinion based on the work undertaken in the course of our audit:
• The information given in the trustees’ report, which includes the directors’ report and the strategic report prepared for the purposes of company law, for the financial year for which the financial statements are prepared is consistent with the financial statements; and
• The strategic report and the directors’ report included within the trustees’ report have been prepared in accordance with applicable legal requirements

Matters on which we are required to report by exception
In light of the knowledge and understanding of the group and the charitable company and their environment obtained in the course of the audit, we have not identified material misstatements in the strategic report or the directors’ report included within the trustees’ report.

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 and the Charities Accounts (Scotland) Regulations 2006 require us to report to you if, in our opinion:
• Adequate and proper accounting records have not been kept; or
• The financial statements are not in agreement with the accounting records and returns; or
• Certain disclosures of trustees’ remuneration specified by law are not made; or
• We have not received all the information and explanations we require for our audit

Responsibilities of trustees
As explained more fully in the trustees’ responsibilities statement set out on page 17, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the group’s or the charitable company’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

Auditor’s responsibilities for the audit of the financial statements
We have been appointed as auditor under section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005 and under the Companies Act 2006 and report in accordance with the Acts and relevant regulations made or having effect thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council’s website at frc.org.uk/auditorsresponsibilities. This description forms part of our auditor’s report.

Use of our report
This report is made solely to the charitable company’s members, as a body, in accordance with Chapter 3 of part 16 of the Companies Act 2006, and to the charitable company’s trustees, as a body, in accordance with Regulation 10 of the Charities Accounts (Scotland) Regulations 2006. Our audit work has been undertaken so that we might state to the charitable company’s members and trustees those matters we are required to state to them in an auditor’s report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company, the charitable company’s members as a body and the charitable company’s trustees as a body, for our audit work, for this report, or for the opinions we have formed.

[Signature]
Nicola May
Senior Statutory Auditor
For and on behalf of
Crowe U.K. LLP
Statutory Auditor
London
Date 6 September 2019
Financial statements and notes

Breast Cancer Care

Consolidated Statement of Financial Activities (incorporating an Income and Expenditure Account) for the year ended 31 March 2019

<table>
<thead>
<tr>
<th>Note</th>
<th>Unrestricted Funds £’000</th>
<th>Restricted Funds £’000</th>
<th>2018-19</th>
<th>2017-18</th>
</tr>
</thead>
</table>

Income and endowments from:

Donations and legacies:
- Voluntary income
  - 2: 14,862
  - 3: 3,384
- Project grants
  - 3: 691
Charitable activities
- Other trading activities
  - 4: 3,384
- Investments
  - 5: 140

Total: 18,418

Expenditure on:

Raising funds:
- Costs of generating voluntary income
  - 4,499
- Costs of activities for generating funds
  - 1,913
Charitable activities:
- Support & Inform
  - 7,382
- Influence
  - 850
- Donation to Breast Cancer Now
  - 12,460
Total: 20,692

Net gains/(losses) on investments
- 13: 305

Net income/(expenditure)
- (8,381)

Transfers between funds
- 14: 305

Net movement in funds
- (8,381)

Reconciliation of Funds
- 20 & 21: 8,381

Total funds brought forward at 1 April
- 8,381

Total funds carried forward at 31 March
- 8,447

The deficit for the year of Breast Cancer Care for Companies Act 2006 purposes was (£8,448,000) (2018: deficit of £174,000)

No corporation tax was payable by the charity in the year ended 31st March 2019 (2018: nil).
All the above results derive from continuing activities.

The notes on pages 27 to 38 form part of these accounts.

Breast Cancer Care

Consolidated and Charity Balance Sheets as at 31 March 2019

<table>
<thead>
<tr>
<th>Note</th>
<th>Group 2018-19 £’000</th>
<th>Group 2017-18 £’000</th>
<th>Charity 2018-19 £’000</th>
<th>Charity 2017-18 £’000</th>
</tr>
</thead>
</table>

Fixed Assets
- Intangible Assets
  - 12: 113
- Tangible Assets
  - 13: 710
- Investments
  - 14: 3,868

Current Assets
- Stock
  - 15: 64
- Debtors
  - 16: 3,480
- Investments
  - 17: 11
- Cash at bank and in hand
  - 18: 1,867

Net Current Assets
- 19: 4,340

Creditors: amounts falling due within one year
- 20: (1,082)

Net Current Assets
- 21: 4,340

Creditors: amounts falling due after more than one year
- 22: (324)

Total Net Assets
- 23: 8,447

The Funds of the Charity:
- Restricted income funds
  - 24: 66
- Unrestricted funds:
  - 25: 823
- General funds
  - 26: 7,558
Total Charity Funds
- 27: 8,447

The deficit for the year of the parent charity was £0 (2018: deficit of £174,000)

Approved by the Board of Trustees on 6 September 2019 and signed on its behalf by:

Jill Thompson Chair
Breast Cancer Care

Notes to the Accounts for the year ending 31 March 2019

Company information

The charity is a company limited by guarantee (registered number 02447182), which is incorporated and domiciled in the UK. The address of the registered office during the year was Kennington Business Park, Chester House, 1–3 Brixton Road, London SW9 8DE. On 31 March 2019 Breast Cancer Care merged with Breast Cancer Now to form Breast Cancer Care and Breast Cancer Now a company limited by guarantee in England and Wales (registered number 9347608) and a registered charity in England and Wales (number 1160558), Scotland (number SC045584) and Isle of Man (number 1200). The address of the registered office is 5th Floor, Ibex House, 42–47 Minories, London EC3N 1DY.

1. Accounting policies

Basis of Accounting

The financial statements are prepared under the historical cost convention and in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015) – (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and republic of Ireland (FRS 102) and the Companies Act 2006.

In previous years, the financial statements have been produced on a going concern basis however during 2018/19 the Trustees took the decision to cease operations following the transfer of the charity’s assets, liabilities and activities to Breast Cancer Now which subsequently renamed as Breast Cancer Care and Breast Cancer Now. As a result the accounts have not been prepared on a going concern basis. Breast Cancer Care is now a wholly owned subsidiary of Breast Cancer Care and Breast Cancer Now.

Breast Cancer Care meets the definition of a public benefit entity under FRS 102.

The individual entity accounts of Breast Cancer Care have taken advantage of the disclosure exemption under FRS 102 to separately disclose categories of financial instruments and items of income, expenses, gains or losses relating to instruments as these have been presented on a group basis in the notes to the accounts.

Group accounts

The group accounts consolidate the funds of the charity and its wholly owned trading subsidiary company on a line by line basis. A separate Statement of Financial Activities and Income and Expenditure Account for the charity has not been presented because advantage has been taken of the exemption afforded by section 408 of the Companies Act 2006.

Critical accounting judgements and key sources of estimation uncertainty

In the application of the charity’s accounting policies, which are described in the accounting policies below, trustees are required to make judgements, estimates and assumptions about the carrying values of assets and liabilities that are not readily apparent from other sources. The estimates and underlying assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects the current and future periods.

Breast Cancer Care

Consolidated Cashflow Statement for the year ended 31 March 2019

<table>
<thead>
<tr>
<th></th>
<th>2018-19</th>
<th>2017-18</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net cash provided by operating activities (a)</td>
<td>3,823</td>
<td>(1,160)</td>
</tr>
<tr>
<td>Cash flows from investing activities:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cash withdrawals from investments</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Purchase of property, plant and equipment</td>
<td>156</td>
<td>221</td>
</tr>
<tr>
<td>Proceeds from sale of investments</td>
<td>-</td>
<td>4,116</td>
</tr>
<tr>
<td>Purchase of investments</td>
<td>-</td>
<td>(4,114)</td>
</tr>
<tr>
<td>Net cash provided by investing activities</td>
<td>156</td>
<td>219</td>
</tr>
<tr>
<td>Increase in cash in the year</td>
<td>3,667</td>
<td>(1,379)</td>
</tr>
<tr>
<td>Change in cash and cash equivalents in the reporting period</td>
<td>3,667</td>
<td>(1,379)</td>
</tr>
<tr>
<td>Cash and cash equivalents at the beginning of the reporting period</td>
<td>1,878</td>
<td>3,257</td>
</tr>
<tr>
<td>Cash and cash equivalents at the end of the reporting period</td>
<td>5,545</td>
<td>1,878</td>
</tr>
</tbody>
</table>

(a) Reconciliation of net income/(expenditure) to net cash flow from operating activities

Net incoming/(outgoing) resources for the reporting period (from the Statement of Financial Activities) | (8,753) | (103) |
Adjustments for: |         |         |
Depreciation and amortisation charges | 212     | 307     |
Donation to Breast Cancer Now | 12,466   |         |
(Increase) in stocks | 8       | 24      |
(Increase) in debtors | 69      | (1,161) |
(Decrease)/increase in creditors | (179)   | (227)   |
Net cash provided by operating activities | 3,823   | (1,160) |

(b) Analysis of cash and cash equivalents

<table>
<thead>
<tr>
<th></th>
<th>31 March</th>
<th>Cashflow 1 April</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2019</td>
<td>2018</td>
</tr>
<tr>
<td>Cash at bank and in hand</td>
<td>5,545</td>
<td>3,667</td>
</tr>
<tr>
<td>Notice deposits (less than 3 months)</td>
<td>-</td>
<td>11</td>
</tr>
<tr>
<td>Total cash and cash equivalents</td>
<td>5,545</td>
<td>3,667</td>
</tr>
</tbody>
</table>
The key sources of estimation uncertainty that have a significant effect on the amounts recognised in the financial statements are described in the accounting policies and are summarised below:

### Incoming resources
All incoming resources are included when the charity is legally entitled to the income, is reasonably certain of receipt and the amount can be measured with reasonable accuracy.

For legacies, recognition is the earlier of the estate accounts being approved or cash being received. Income from will or revocatory trusts is not recognised until the life interest has passed away.

Donated services are included at the value to the charity where this can be quantified, which is the amount the charity would have been willing to pay to obtain services or facilities of equivalent economic benefit on the open market. In accordance with the Charities SORP (FRS 102) no amounts are included in the financial statements for services donated by volunteers. Refer to the trustees’ annual report for more information about their contribution. Gifts in kind are included at the value to the charity or, where resold, at the resale price.

Income relating to events taking place after the year end is deferred and included in creditors. The relevant costs associated with these events are also deferred and included in prepayments.

Rental income is recognised on a straight line basis over the term of the lease.

### Resources expended
All expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all costs related to the category. Where costs cannot be attributed directly to the individual areas they have been apportioned to activities on a basis consistent with use of the resources. All overheads have been apportioned either on the basis of the number of staff engaged in each activity or the floor space occupied by the staff as appropriate.

Fundraising costs are those incurred in seeking voluntary contributions and do not include the costs of disseminating information in support of the charitable activities or the costs of delivering charitable services.

Support costs are those costs incurred directly in support of expenditure on the objects of the charity. Support costs together with governance costs are apportioned between the key activities undertaken in the year (see note 6).

### Taxation
Breast Cancer Care, as a registered charity, is exempt from taxation of income falling within Section 505 of the Taxes Act 1988 or Section 256 of the Taxation of Chargeable Gains Act 1992 to the extent that this is applied to its charitable objectives. No tax charge has arisen in its trading subsidiary, Breast Cancer Care Trading Ltd, because of its policy of gifting its taxable profits to the parent charity each year. Breast Cancer Care has no similar exemption from VAT. Irrecoverable VAT is included in the cost of those items to which it relates. All other income and expenses are net of VAT.

### Intangible fixed assets
Intangible fixed assets costing more than £1,000 are capitalised. Depreciation is charged on a straight line basis to write off the cost of the assets over their useful life as follows:

- Website development costs – 25 to 33% per annum

### Fixed asset investment
Investments are valued in the balance sheet at their market value at the balance sheet date. The Statement of Financial Activities includes the net gains and losses arising on revaluations and disposals throughout the year. Income from investments is included in the Statement of Financial Activities on a receivable basis.

### Stock
Stock comprises Christmas cards, pin badges and other merchandise for sale, valued at the lower of cost and net realisable value.

### Debtors
Trade and other debtors are recognised at the settlement amount due. Prepayments are values at the amount prepaid.

### Current investments
Current investments include cash held on deposit accounts with a maturity date of less than one year.

### Cash at bank and in hand
Cash at bank and cash in hand includes cash held for immediate use by the charity.

### Creditors and provisions
Creditors and provisions are recognised where the charity has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors and provisions are normally recognised at their settlement amount.

### Financial instruments
The charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value.

### Publications expenses
Expenditure on publications is written off in the period such cost is incurred, as these have no resale value.

### Leases
Rents under operating leases are charged on a straight line basis over the term of the lease. Further information on charges in the year and future commitments is given in Note 8.

### Fund Accounting
Restricted, designated and general funds are separately disclosed, as set out in Notes 20 and 21. The different funds held are defined as follows:

- Restricted funds are subject to specific restrictions imposed by the donor or by the nature of the appeal
- Designated funds are set aside at the discretion of the trustees for specific purposes. Details of the specific designated funds are given in Note 20
- Other charitable funds are available to spend at the discretion of the trustees in furtherance of Breast Cancer Care’s charitable objectives
Pension costs
Permanent employees are entitled to join the group Personal Pension Scheme provided by Standard Life, which was established on 14 April 1998. This is a contributory defined contribution scheme, administered by an independent scheme administrator. Scheme funds are independent of the charity and invested with Standard Life. Payments to the pension scheme are a fixed percentage of salary for each employee, and the amount charged in the income and expenditure account is the cost of the fixed percentage along with the costs of the independent scheme administrator. The cost of providing this pension scheme is charged to the Statement of Financial Activities when it is incurred.

Breast Cancer Care

Notes to the Accounts for the year ended 31 March 2019

2. Voluntary income

<table>
<thead>
<tr>
<th></th>
<th>Unrestricted</th>
<th>Restricted</th>
<th>2018-19</th>
<th>2017-18</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Funds £'000</td>
<td>Funds £'000</td>
<td>Total £'000</td>
<td>Total £'000</td>
</tr>
<tr>
<td>Individual and Other Donations</td>
<td>11,986</td>
<td>163</td>
<td>12,149</td>
<td>12,091</td>
</tr>
<tr>
<td>Corporate Donations</td>
<td>1,235</td>
<td>266</td>
<td>1,501</td>
<td>1,501</td>
</tr>
<tr>
<td>Corporate Sponsorships through Trading Subsidiary</td>
<td>1,472</td>
<td>-</td>
<td>1,472</td>
<td>1,472</td>
</tr>
<tr>
<td>Legacies</td>
<td>287</td>
<td>3</td>
<td>290</td>
<td>290</td>
</tr>
<tr>
<td></td>
<td>14,992</td>
<td>492</td>
<td>15,484</td>
<td>15,363</td>
</tr>
</tbody>
</table>

Voluntary income was £15,294,000 (2018: £11,453,000), of which £14,684,000 was unrestricted (2018: £11,060,000) and £610,000 was restricted (2018: £393,000).

Individual and other donations includes gifts in kind of £604,564 (2018: £294,420) and corporate donations includes gifts in kind of £16,201 (2018: £23,601).

At 31 March 2019, in addition to legacy income that has been included in the accounts, the charity expects to benefit from legacies to an approximate value of £138,000 (2018: £152,000) from estates for which the administration has yet to be finalised.

It is not possible to account for the value our volunteers bring to the charity, but they donate their time to a range of activities across the organisation, including fundraising efforts, campaigning and the delivery of services, as described in the strategic report.

3. Project grants

<table>
<thead>
<tr>
<th></th>
<th>2018-19</th>
<th>2017-18</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Total £'000</td>
<td>Total £'000</td>
</tr>
<tr>
<td>Moondance Foundation</td>
<td>194</td>
<td>165</td>
</tr>
<tr>
<td>BIG Lottery Fund</td>
<td>272</td>
<td>130</td>
</tr>
<tr>
<td>The Saracens Sport Foundation</td>
<td>55</td>
<td>50</td>
</tr>
<tr>
<td>Future Dreams</td>
<td>-</td>
<td>38</td>
</tr>
<tr>
<td>The William Grant Gordon Foundation</td>
<td>-</td>
<td>35</td>
</tr>
<tr>
<td>The Jane Hodge Foundation</td>
<td>24</td>
<td>32</td>
</tr>
<tr>
<td>Esiee Lauder Foundation</td>
<td>-</td>
<td>25</td>
</tr>
<tr>
<td>The Robertson Trust</td>
<td>-</td>
<td>15</td>
</tr>
<tr>
<td>The Ellen Kane Charitable Trust</td>
<td>-</td>
<td>10</td>
</tr>
<tr>
<td>Rangers Charity Foundation</td>
<td>-</td>
<td>10</td>
</tr>
<tr>
<td>The Edith Murphy Foundation</td>
<td>-</td>
<td>10</td>
</tr>
<tr>
<td>The Scarborough Group Foundation</td>
<td>10</td>
<td>10</td>
</tr>
<tr>
<td>The Zochonis Charitable Trust</td>
<td>-</td>
<td>6</td>
</tr>
<tr>
<td>The Eveson Charitable Trust</td>
<td>6</td>
<td>6</td>
</tr>
<tr>
<td>The PF Charitable Trust</td>
<td>-</td>
<td>5</td>
</tr>
<tr>
<td>The Simon Gibson Charitable Trust</td>
<td>-</td>
<td>5</td>
</tr>
<tr>
<td>The Hugh Fraser Foundation</td>
<td>-</td>
<td>10</td>
</tr>
<tr>
<td>The Northwood Charitable Trust</td>
<td>-</td>
<td>10</td>
</tr>
<tr>
<td>Various grant giving trusts</td>
<td>120</td>
<td>31</td>
</tr>
<tr>
<td></td>
<td>991</td>
<td>211</td>
</tr>
</tbody>
</table>

4. Activities for generating funds

<table>
<thead>
<tr>
<th></th>
<th>Unrestricted Funds £'000</th>
<th>Restricted Funds £'000</th>
<th>Total £'000</th>
<th>2018-19</th>
<th>2017-18</th>
</tr>
</thead>
<tbody>
<tr>
<td>Events Income</td>
<td>3,183</td>
<td>3</td>
<td>3,186</td>
<td>3,693</td>
<td></td>
</tr>
<tr>
<td>Merchandising Income</td>
<td>201</td>
<td>-</td>
<td>201</td>
<td>302</td>
<td></td>
</tr>
<tr>
<td></td>
<td>3,384</td>
<td>3</td>
<td>3,387</td>
<td>3,995</td>
<td></td>
</tr>
</tbody>
</table>

Income from activities for generating funds was £3,387,000 (2018: £3,995,000), of which £3,384,000 (2018: £3,984,000) was unrestricted, and £3,000 (2018: £9,000) was restricted.

5. Investment income

<table>
<thead>
<tr>
<th></th>
<th>Unrestricted Funds £'000</th>
<th>Restricted Funds £'000</th>
<th>Total £'000</th>
<th>2018-19</th>
<th>2017-18</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interest Received</td>
<td>2</td>
<td>-</td>
<td>2</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Investment Income</td>
<td>138</td>
<td>-</td>
<td>138</td>
<td>158</td>
<td></td>
</tr>
<tr>
<td></td>
<td>140</td>
<td>-</td>
<td>140</td>
<td>158</td>
<td></td>
</tr>
</tbody>
</table>
Breast Cancer Care

Notes to the Accounts for the year ended 31 March 2019

6. Analysis of expenditure

<table>
<thead>
<tr>
<th>Activities for generating voluntary income</th>
<th>2018-19</th>
<th>2017-18</th>
</tr>
</thead>
<tbody>
<tr>
<td>Funds</td>
<td>£'000</td>
<td>£'000</td>
</tr>
<tr>
<td>Support</td>
<td>£'000</td>
<td>£'000</td>
</tr>
<tr>
<td>Influence</td>
<td>£'000</td>
<td>£'000</td>
</tr>
<tr>
<td>Total</td>
<td>£'000</td>
<td>£'000</td>
</tr>
<tr>
<td>Direct costs</td>
<td>£'000</td>
<td>£'000</td>
</tr>
<tr>
<td>Staff costs</td>
<td>1,534</td>
<td>651</td>
</tr>
<tr>
<td>Direct costs</td>
<td>3,882</td>
<td>328</td>
</tr>
<tr>
<td>Other direct costs</td>
<td>2,251</td>
<td>910</td>
</tr>
<tr>
<td>VAT Recovered</td>
<td>1,197</td>
<td>1,021</td>
</tr>
<tr>
<td>Trustee &amp; trustee meeting expenses</td>
<td>67</td>
<td>66</td>
</tr>
<tr>
<td>VAT Recovered</td>
<td>3,785</td>
<td>3,181</td>
</tr>
<tr>
<td>Support costs</td>
<td>1,561</td>
<td>1,267</td>
</tr>
<tr>
<td>Financing Technology</td>
<td>131</td>
<td>56</td>
</tr>
<tr>
<td>Finance &amp; Supporter Services</td>
<td>239</td>
<td>135</td>
</tr>
<tr>
<td>Public Awareness</td>
<td>6</td>
<td>6</td>
</tr>
<tr>
<td>Facilities</td>
<td>261</td>
<td>111</td>
</tr>
<tr>
<td>Human Resources</td>
<td>128</td>
<td>55</td>
</tr>
<tr>
<td>Governance</td>
<td>26</td>
<td>11</td>
</tr>
<tr>
<td>VAT Recovered</td>
<td>41</td>
<td>17</td>
</tr>
<tr>
<td>Trustee &amp; trustee meeting expenses</td>
<td>4</td>
<td>6</td>
</tr>
<tr>
<td>VAT Recovered</td>
<td>714</td>
<td>302</td>
</tr>
<tr>
<td>Total costs</td>
<td>4,429</td>
<td>3,913</td>
</tr>
<tr>
<td>Support costs above include the following governance costs:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CEO office salary costs</td>
<td>70</td>
<td>67</td>
</tr>
<tr>
<td>Auditors remuneration</td>
<td>22</td>
<td>28</td>
</tr>
<tr>
<td>Total</td>
<td>92</td>
<td>105</td>
</tr>
</tbody>
</table>

Expenditure total £15,831,000 (2018: £16,295,000), of which £14,945,000 (2018: £15,082,000) was unrestricted, and £1,166,000 (2018: £1,213,000) was restricted. Restricted funds were used for generating voluntary income (£2,913,000) to support and inform staff, (£1,114,000) to support and inform management personnel of the charity were £800,416 (2018: £570,669) and (£8,000, 2018: £39,000). The key management personnel of the charity and the group comprise the trustees, the Chief Executive Officer, and the directors. As indicated in note 9, none of the trustees were paid any remuneration or received any other benefits. The total employee benefits of the key management personnel of the charity were £800,416 (2018: £570,669).

7. Total Resources Expended

<table>
<thead>
<tr>
<th>Resources expended include:</th>
<th>2018-19</th>
<th>2017-18</th>
</tr>
</thead>
<tbody>
<tr>
<td>Auditors’ remuneration:</td>
<td>£’000</td>
<td>£’000</td>
</tr>
<tr>
<td>- Audit fees</td>
<td>18</td>
<td>24</td>
</tr>
<tr>
<td>- Tax advisory services</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>Depreciation and amortisation</td>
<td>212</td>
<td>307</td>
</tr>
<tr>
<td>Auditor remuneration</td>
<td>22</td>
<td>28</td>
</tr>
</tbody>
</table>

8. Lease Commitments - leases

Operating lease rentals of £784,242 (2018: £707,586) were paid in respect of equipment, and property and facilities held under leases during the year. In the coming year, the charity is committed to paying the following amounts in respect of operating leases, expiring:

<table>
<thead>
<tr>
<th>Equipment</th>
<th>Property and Facilities</th>
<th>2018-19</th>
<th>2017-18</th>
</tr>
</thead>
<tbody>
<tr>
<td>£’000</td>
<td>£’000</td>
<td>£’000</td>
<td>£’000</td>
</tr>
<tr>
<td>Between one and five years</td>
<td>-</td>
<td>-</td>
<td>1,826</td>
</tr>
<tr>
<td>More than five years</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

9. Trustees’ remuneration and expenses

<table>
<thead>
<tr>
<th>Trustees’ remuneration and expenses</th>
<th>2018-19</th>
<th>2017-18</th>
</tr>
</thead>
<tbody>
<tr>
<td>£’000</td>
<td>£’000</td>
<td></td>
</tr>
<tr>
<td>Trustees’ expenses reimbursed</td>
<td>6</td>
<td>7</td>
</tr>
</tbody>
</table>

None of the trustees have been paid any remuneration or received any other benefits from any employment with the charity (2018: None). Out of pocket expenses for travel and subsistence were reimbursed to 6 trustees (2018: 6).

Breast Cancer Care

Notes to the Accounts for the year ended 31 March 2019

10. Staff costs

<table>
<thead>
<tr>
<th>Staff costs</th>
<th>2018-19</th>
<th>2017-18</th>
</tr>
</thead>
<tbody>
<tr>
<td>£’000</td>
<td>£’000</td>
<td></td>
</tr>
<tr>
<td>Salaries</td>
<td>6,500</td>
<td>6,571</td>
</tr>
<tr>
<td>Social Security costs</td>
<td>674</td>
<td>681</td>
</tr>
<tr>
<td>Pension contributions</td>
<td>614</td>
<td>504</td>
</tr>
</tbody>
</table>

The number of employees whose emoluments as defined for taxation purposes amounted to over £60,000 in the year was as follows:

<table>
<thead>
<tr>
<th>No.</th>
<th>£230,001 - £240,000</th>
</tr>
</thead>
<tbody>
<tr>
<td>7</td>
<td></td>
</tr>
</tbody>
</table>

All employees earning more than £60,000 participated in the pension scheme. Contributions paid in respect of these individuals in the year totalled £30,485 (2018: £50,727).

The average weekly number of employees, calculated on a full time equivalent basis, analysed by function was:

<table>
<thead>
<tr>
<th>Resources</th>
<th>2018-19</th>
<th>2017-18</th>
</tr>
</thead>
<tbody>
<tr>
<td>£’000</td>
<td>£’000</td>
<td>£’000</td>
</tr>
<tr>
<td>CEO office salary costs</td>
<td>70</td>
<td>67</td>
</tr>
<tr>
<td>Auditors remuneration</td>
<td>22</td>
<td>28</td>
</tr>
<tr>
<td>Total</td>
<td>92</td>
<td>105</td>
</tr>
</tbody>
</table>
Breast Cancer Care

Notes to the Accounts for the year ended 31 March 2019

12. Tangible Fixed Assets

<table>
<thead>
<tr>
<th>Group and Charity</th>
<th>Leasehold Improvements &amp; Fittings</th>
<th>Furniture &amp; Fixtures</th>
<th>Computers &amp; Equipment</th>
<th>Total Tangible Assets</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cost</td>
<td>£'000</td>
<td>£'000</td>
<td>£'000</td>
<td>£'000</td>
</tr>
<tr>
<td>At 1 April 2018</td>
<td>203</td>
<td>286</td>
<td>1,343</td>
<td>1,832</td>
</tr>
<tr>
<td>Additions</td>
<td>7</td>
<td></td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Disposals</td>
<td></td>
<td></td>
<td>149</td>
<td>158</td>
</tr>
<tr>
<td>At 31 March 2019</td>
<td>219</td>
<td>286</td>
<td>1,492</td>
<td>1,952</td>
</tr>
</tbody>
</table>

Depreciation

<table>
<thead>
<tr>
<th>At 1 April 2018</th>
<th>£'000</th>
<th>73</th>
<th>86</th>
<th>363</th>
<th>1,122</th>
</tr>
</thead>
<tbody>
<tr>
<td>Charge for the year</td>
<td>16</td>
<td>9</td>
<td>129</td>
<td>154</td>
<td></td>
</tr>
<tr>
<td>Disposals</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>At 31 March 2019</td>
<td>89</td>
<td>95</td>
<td>1,092</td>
<td>1,276</td>
<td></td>
</tr>
</tbody>
</table>

13. Fixed asset investments

<table>
<thead>
<tr>
<th>Group and Charity</th>
<th>2018-19</th>
<th>2017-18</th>
</tr>
</thead>
<tbody>
<tr>
<td>Market value at 1 April</td>
<td>£'000</td>
<td>£'000</td>
</tr>
<tr>
<td>Transfers to cash reserves</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Purchases</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Disposal Proceeds</td>
<td>(4,114)</td>
<td>(4,114)</td>
</tr>
<tr>
<td>Net realised (losses)/gains during the year</td>
<td>305</td>
<td>88</td>
</tr>
<tr>
<td>Market value of listed investments at 31 March</td>
<td>£'000</td>
<td>£'000</td>
</tr>
<tr>
<td>Transfers from current investments 31 March</td>
<td>4,173</td>
<td>7,392</td>
</tr>
<tr>
<td>Transfers to BCN (4,173)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Market value of fixed asset investments at 31 March</td>
<td>£'000</td>
<td>£'000</td>
</tr>
<tr>
<td>Historical cost at 31 March</td>
<td>£'000</td>
<td>£'000</td>
</tr>
</tbody>
</table>

14. Debtors

<table>
<thead>
<tr>
<th>Group</th>
<th>2018-19</th>
<th>2017-18</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bank of Scotland</td>
<td>£'000</td>
<td>£'000</td>
</tr>
<tr>
<td>Barclays</td>
<td>1,336</td>
<td>772</td>
</tr>
<tr>
<td>Other Banks</td>
<td>181</td>
<td>22</td>
</tr>
<tr>
<td>Prepayments and accrued income</td>
<td>1,922</td>
<td>2,547</td>
</tr>
<tr>
<td>Subsidiary company</td>
<td>1,220</td>
<td>1,160</td>
</tr>
<tr>
<td>Transfer to BCN (3,412)</td>
<td>-</td>
<td>(3,845)</td>
</tr>
<tr>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

15. Current Investments

<table>
<thead>
<tr>
<th>Group</th>
<th>2018-19</th>
<th>2017-18</th>
</tr>
</thead>
<tbody>
<tr>
<td>Money Market and Bank Deposits</td>
<td>£'000</td>
<td>£'000</td>
</tr>
<tr>
<td>Transfer to BCN (1,511)</td>
<td>-</td>
<td>(1,511)</td>
</tr>
</tbody>
</table>

Notes to the Accounts for the year ended 31 March 2019

16. Creditors: Amounts falling due within one year:

<table>
<thead>
<tr>
<th>Group</th>
<th>2018-19</th>
<th>2017-18</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trade Creditors</td>
<td>£'000</td>
<td>£'000</td>
</tr>
<tr>
<td>Other Creditors</td>
<td>61</td>
<td>71</td>
</tr>
<tr>
<td>Accruals</td>
<td>434</td>
<td>391</td>
</tr>
<tr>
<td>Deferred income</td>
<td>279</td>
<td>248</td>
</tr>
<tr>
<td>Taxation and Social Security</td>
<td>233</td>
<td>261</td>
</tr>
<tr>
<td>Subsidiary company</td>
<td>Transfer to BCN (1,046)</td>
<td>-</td>
</tr>
<tr>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

Deferred income includes amounts received for fundraising events taking place in the next financial year. During the year £0 of income was deferred (2018: £246,427) and £246,427 of income was released (2018: £389,679).

17. Creditors: Amounts falling due after one year:

<table>
<thead>
<tr>
<th>Group</th>
<th>2018-19</th>
<th>2017-18</th>
</tr>
</thead>
<tbody>
<tr>
<td>Other Creditors</td>
<td>159</td>
<td>324</td>
</tr>
<tr>
<td>Transfer to BCN (159)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

18. Provisions for liabilities

<table>
<thead>
<tr>
<th>Group and Charity</th>
<th>1 April Transfer to BCN</th>
<th>31 March Release</th>
</tr>
</thead>
<tbody>
<tr>
<td>Office lease commitments</td>
<td>£'000</td>
<td>£'000</td>
</tr>
<tr>
<td>-</td>
<td>260</td>
<td>-</td>
</tr>
</tbody>
</table>

Provisions relate to the potential dilapidations and exit costs associated with our four offices. One lease will expire in 2018 and resulted in the increase in the provision.

19. Restricted Funds

<table>
<thead>
<tr>
<th>Group and Charity</th>
<th>Balance at 1 April Transfer to BCN</th>
<th>Balance at 31 March</th>
</tr>
</thead>
<tbody>
<tr>
<td>Litigation</td>
<td>£'000</td>
<td>£'000</td>
</tr>
<tr>
<td>-</td>
<td>324</td>
<td>-</td>
</tr>
<tr>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

The Big Lottery Fund - This grant is to fund our development of BECCA app

The Lavender Trust Fund at Breast Cancer Care raised funds specifically to provide support and information services for younger women.

Moondance Foundation – this grant is to fund our Moving Forward courses in Wales, specifically.

Client Services restricted funds have been received from a variety of donors funding a range of our client services activities during the year.
Breast Cancer Care

Notes to the Accounts for the year ended 31 March 2019

20. Unrestricted Funds

<table>
<thead>
<tr>
<th>Funds</th>
<th>1 April 2017</th>
<th>Income</th>
<th>Expenditure</th>
<th>Transfer</th>
<th>Investments</th>
<th>31 March 2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>General funds</td>
<td>£'000</td>
<td>£'000</td>
<td>£'000</td>
<td>£'000</td>
<td>£'000</td>
<td>£'000</td>
</tr>
<tr>
<td>Fixed assets fund</td>
<td>923</td>
<td>296</td>
<td>(396)</td>
<td>-</td>
<td>623</td>
<td>923</td>
</tr>
<tr>
<td>Total unrestricted funds</td>
<td>9,558</td>
<td>18,418</td>
<td>(27,104)</td>
<td>-</td>
<td>305</td>
<td>-</td>
</tr>
</tbody>
</table>

21. Analysis of Group Net Assets between Funds

<table>
<thead>
<tr>
<th>Funds</th>
<th>1 April 2017</th>
<th>Income</th>
<th>Expenditure</th>
<th>Transfer</th>
<th>Investments</th>
<th>31 March 2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>General funds</td>
<td>£'000</td>
<td>£'000</td>
<td>£'000</td>
<td>£'000</td>
<td>£'000</td>
<td>£'000</td>
</tr>
<tr>
<td>Fixed assets fund</td>
<td>923</td>
<td>296</td>
<td>(396)</td>
<td>-</td>
<td>623</td>
<td>923</td>
</tr>
<tr>
<td>Total unrestricted funds</td>
<td>8,381</td>
<td>18,262</td>
<td>(26,125)</td>
<td>-</td>
<td>305</td>
<td>-</td>
</tr>
</tbody>
</table>

22. Financial Instruments

At the balance sheet date the consolidated group held financial assets at amortised cost comprising cash and short term deposits, stock, trade debtors, other debtors and accrued income of £0 (2018: £5,161,000) and financial liabilities at amortised cost, comprising trade creditors, other creditors and accruals at £0 (2018: £573,000). Total interest income received in respect of financial assets held at amortised cost totalled £1,000 (2018: £1,000).

The charity held assets at fair value through income and expenditure of £0 (2018: £3,868,000). Movements in the year through the statement of financial activities comprised income of £0 (2018: £158,000) and losses of £0 (2018 losses of £71,000).

Breast Cancer Care

Notes to the Accounts for the year ended 31 March 2019

23. Subsidiary Company

The charity owns the whole of the issued ordinary share capital of Breast Cancer Care Trading Limited, a company registered in England (company no. 02681072). The subsidiary is used for trading activities, including the sale of merchandise, cause-related marketing agreements, corporate sponsorships and events subject to tax.

All activities have been consolidated on a line by line basis in the Statement of Financial Activities.

The total net profit of the company is gifted to the charity.

A summary of the results of the subsidiary is shown below:

<table>
<thead>
<tr>
<th>Merchandising</th>
<th>Corporate Income</th>
<th>Events</th>
<th>Other</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>£'000</td>
<td>£'000</td>
<td>£'000</td>
<td>£'000</td>
<td>£'000</td>
</tr>
</tbody>
</table>

Breast Cancer Care Nursing Network – which provides our ‘Living with Secondary Breast Cancer’ and ‘Younger Women Together with Secondary’ Service. The income also supported our Helpline and Breast Cancer Care Nursing Network – which provides educational resources, learning events, regular news publications and training, currently for 1,145 specialist breast care nurses across the UK. All donations strictly adhere to our policy on working with pharmaceutical companies, and are in accordance with the requirements of the ABPI Code of Practice for the Pharmaceutical Industry.
Breast Cancer Care
Notes to the Accounts for the year ended 31 March 2019

29. Defined Contribution Pension Scheme

The company provides defined contribution schemes for all employees. The amount charged to the statement of financial activities is the contribution payable in the year and amounted to £613,796 (2018: £503,845).
Thank you

All the healthcare professionals who reviewed our information and spoke at our services
Amgen Ltd
Anita Watson
Asda for the incredible Tickled Pink campaign
Ayr Rugby Club
Babebth Nadell
Baker McKenzie
Balance Training
Barclays Bank
Betty and Colin Hart
Big Yellow Self Storage Company Ltd
Billy and Gail Allen
Bob and Christine Sturgess
Boux Avenue
Boy George and Kevin O’Dowd
Breast Cancer Hope
Bridget Buckton BT
Buyagift.com
BWT
Caroline Hills
Caroline Humber
Carolyn Collard
Charlie Hainsworth
Christine Sturgess for chairing The Show London committee and to all our committee members
Claire McDonnell
Claire Myerson
Curves
Cynthia Langdon
Dawn Tunbridge
Dean Walsh
Deborah Hubbard
Dee Hartland-Swan
delicious. Magazine
Dorothy Perkins
Dream Challenges team for their continued support as part of the Women v cancer partnership
Duncan Spence
Dundee Stars
Eleanor Meade
ELEMIS
Ellen Kane Trust
Essex Fundraising Group
Estée Lauder
Eversheds Sutherland
Fairfax & Favor
Fiona Trehanne
Fiorelli (Global Brands Group)
Folli Follie
Freshfields Bruckhaus Deringer
Glasgow Fundraising Group
Glasgow High Kelvinside RFC
Greenberg Traurig LLP
GSK
Haydn Derry
Hayley Carpenter-Priest
Hilary Alexander, Deborah Britz and the team of stylists
Hilton Hotels Ltd and HLT Stakis Operator Ltd
HIQ
House of Fraser
Ian Tod
Jackie Scully and Duncan Sloan
Jason Haigh-Ellery
JML
JM Paterson Ltd
Jo Myatt
Jo Taylor
Joanne and Chris Thomson
Jobs Go Public
Joint
Jonny Lee-Kemp
Julie Croft
Kate Wauchope
King & Spalding LLP
Lakeside Leisure Group
Latham & Watkins LLP
Leo Burnett
Linda Dye
Linda Larter MBE, Chief Executive Sevenoaks Town Council
Lindt
Liz Mackay
L Lynch Plant Hire & Haulage Ltd
Look Good Feel Better
Lorraine Hathorn
Lurline Thomas
Malini PR
Mark Master
MCL Create
Milk_Shake Haircare
Monsoon Accessorize
Murgitroyd
National Lottery Community Fund
Nick Miles
Norton Rose Fulbright
Nova Dando
Novartis Pharmaceuticals UK Ltd
OFFICE
Our patrons of the Care Collective, Paul Pester and the Saracens Sport Foundation and members of the Care Collective Jonathan Agnew, Mark Astaire, Jonny Barbarow, Emma Burns, Keith Carby, Tracy De Groose, Simon Fox, Chris Harrison, Harold and Stephanie Joaknckeh-Kogels, Michael and Judy Joseph, Mary Mayall, Lori Meakin, Andrew and Val Moore, Anne O’Neill, Angela Quinn, Frank Runge, The Scarborough Group Foundation, Louise Tail and all our anonymous members and contributors
Palmer’s
Pamela Penfold
Park Plaza Hotels and Resorts
Pfizer Ltd
Players of The People’s Postcode Lottery
PM Solutions
Premier Paper
QBE European Operations QVC UK
Radisson Hotel Glasgow
RBS
Reed Smith LLP
ReFashion
Ridley Scott Associates
Rieves
Roger Jones Auctioneers
Sarah Alton
Safnan Seats
Santander
Sassoon
Sidley Austin LLP
Silverstone Woodlands Campsite
Skechers
Smint (Perfetti Van Melle)
Southside Ladies Lunch Committee, Glasgow
Spabreaks.com
Spencer Dennis
SportsPesa Racing Point F1 Team
Steph Harrison
Steve Lyons and Richard Cockburn
Sturdy by Design
Sunday Mail
Surrey Fundraising Group
Talitig Ltd
The Agnes Hunter Charitable Trust
The Bertram Nursery Group
The Carols by Candlelight London committee members
The Edith Murphy Foundation
The Evening Standard
The Eveson Charitable Trust
The Hodge Foundation
The Hugh Fraser Foundation
The Moondance Foundation for funding the expansion of Moving Forward services across Wales
The Northwood Charitable Trust
The PF Charitable Trust
The Robertson Trust
The Show Scotland Committee
The Souter Charitable Trust
The William Grant Foundation for their generous support of Breast Cancer Care Scotland
The Zochonis Charitable Trust
Tour de SPFL Committee
Tracy Whiteaker
TT Litho Printers
Wales Events Committee
Wayne Palmer and Dale Hattey
Wilkie Farr & Gallagher LLP
Wilko Retail Limited
Woman & Home
Workspace
Wright Hassall LLP

A special thank you to each person who very kindly remembered Breast Cancer Care’s work in their Will
About us: our legal and administrative details

Please note: The following details applied to Breast Cancer Care up to March 31 2019, the time period covered by this report. Thereafter Breast Cancer Care became part of a new united charity under the name Breast Cancer Care and Breast Cancer Now, with different charity details, structure, governance and management. Due diligence was applied in making these changes, taking into consideration the arrangements of both the uniting charities. For more details visit breastcancercare.org.uk/united

Royal Patron
Her Royal Highness The Duchess of Kent GCVO

Patrons
Joan, Baroness Bakewell DBE
Cherie Blair CBE QC
Geri Horner
Allan Leighton
Professor Trevor Powles CBE
Professor Ian Smith

Ambassadors
Kaye Adams
Jonathan Ansell
Alexandra Burke
Sara Carello
Vanessa Feltz
Leigh Halfpenny
Jane Hinnrichs
Denise Lewis OBE
Amanda Mealing
Diama Moran
Mike Phillips
Lisa Snowdon
Meera Syal CBE
Denise Van Outen

Founder
Betty Westgate MBE (1919–2000)

Board of Trustees
Emma Burns, Chair (resigned 31 March 2019)
Dr Marion Lewis, Vice-Chair (resigned 31 March 2019)
Jill Thompson, Treasurer
Mark Astaire (resigned 31 March 2019)
Barbara Brown (resigned 31 March 2019)
Susan Gallone (appointed 1 April 2019)
Sonia Gayle (resigned 31 March 2019)
Dr Alison Jones (resigned 31 March 2019)
Polly McGivern (appointed 1 April 2019)
Delyth Morgan (appointed 1 April 2019)
Nick Morris (resigned 31 March 2019)
Candice Nichol (resigned 31 March 2019)
Jill Pask (resigned 19 September 2018)

Chief Executive
Samia al Qadhi

Executive Directors
David Crosby (Services and Engagement)
Jenny Fernando (Finance and Resources)
Steve Lucas (Fundraising and Marketing)
Dr Emma Pennery CBE (Clinical and Information)

Board subcommittees
Finance and General Purposes
Jill Thompson, Chair
Emma Burns
Nick Morris
Jill Pask (until 19 September 2018)

Investment
Jill Pask, Chair (until 19 September 2018)
Mark Astaire
Candice Nichol
Jill Thompson, Chair (from 19 September 2018)

HR and Remuneration
Nick Morris, Chair
Barbara Brown
Emma Burns
Steve Jenkins (co-opted)

Governance and Nominations
Dr Marion Lewis, Chair
Emma Burns
Dr Alison Jones

Audit and Assurance
Dr Marion Lewis, Chair pro tem
Sonia Gayle
Dr Alison Jones
Jonathan Dancey (co-opted)

Company Secretary
Callum Calder (resigned 28 March 2019)

Registered office
Fifth Floor
Ibex House
42–47 Minories
London EC3N 1DY
Tel 03450920800
Fax 03450920820
www.breastcancercare.org.uk
email info@breastcancercare.org.uk

Auditors
Crowe UK LLP
St Bride’s House
10 Salisbury Square
London EC4Y 8EH

Bankers
HSBC plc
315 Fulham Road
London SW10 9QJ

Investment managers
CCLA
Senator House
85 Queen Victoria Street
London EC4V 4ET

Solicitors
Bates, Wells and Braithwaite
138 Cheapside
London EC2V 6BB

Farrer & Co
66 Lincoln’s Inn Fields
London WC2A 4BX
Breast Cancer Care and Breast Cancer Now united in April 2019 to create one charity for everyone affected by breast cancer.

Our aim is that, by 2050, everyone who develops breast cancer will live and be supported to live well. From research to care, our new charity will have people affected by breast cancer at its heart – providing support for today and hope for the future.

We’ll find ways to prevent the disease, improve early diagnosis, develop new treatments, campaign for better care, and support people coping with the physical and emotional impact of breast cancer.

For breast cancer care, support and information, call us free on 0808 800 6000 or visit breastcancercare.org.uk